Disease & disorder

multiple system atrophy

MONDO:0007803

Multiple system atrophy (MSA) is a neurodegenerative disorder characterized by autonomic failure (cardiovascular and/or urinary), parkinsonism, cerebellar impairment and corticospinal signs with a median survival of 6-9 years.

Clinical trials92
Recruiting24
Drug concepts studied11
Synonyms4

Research intelligence

Directly mapped studies only · unique clinical trials

Current registry observations. Phase counts may overlap. Study start dates are not registry registration dates. Investigational interventions are not approved-treatment recommendations.

Medications under investigation

Verified disease and drug mappings that co-occur within the same study; not evidence of effectiveness.

Loading mapped interventions…

MONDO disease family

Loading verified ontology relationships…

Recruiting studies by city

Loading research-site locations…

Trial status

Loading…

Trial phase

Loading…

Study start year

Loading…

Investigated drug interventions

Loading…
Background context

Multiple system atrophy

Multiple system atrophy (MSA) is a rare neurodegenerative disorder characterized by tremors, slow movement, muscle rigidity, postural instability (collectively known as parkinsonism), autonomic dysfunction and ataxia. This is caused by progressive degeneration of neurons in several parts of the brain including the basal ganglia, inferior olivary nucleus, and cerebellum. MSA was first described in 1960 by Milton Shy and Glen Drager and is also known as Shy–Drager syndrome. Many people affected by MSA experience dysfunction of the autonomic nervous system, which commonly manifests as orthostatic hypotension, impotence, loss of sweating, dry mouth, urinary retention and incontinence. Palsy of the vocal cords is an important and sometimes initial clinical manifestation of the disorder. A prion of the alpha-synuclein protein within affected neurons may cause MSA. About 55% of MSA cases occur in men, with those affected first showing symptoms at the age of 50–60 years. MSA often presents with some of the same symptoms as Parkinson's disease. However, those with MSA generally show little response to the dopamine agonists used to treat Parkinson's disease and only about 9% of MSA patients with tremor exhibit a true parkinsonian pill-rolling tremor (an involuntary, rhythmic movement of the thumb and index finger suggesting the rolling of a pill between them). MSA is distinct from multisystem proteinopathy, a more common muscle-wasting syndrome. MSA is also different from multiple organ dysfunction syndrome, sometimes referred to as multiple organ failure, and from multiple organ...

Background only. Canonical identity remains MONDO; clinical-trial relationships come from ClinicalTrials.gov.

Clinical trials

40 shown
Tributyrin for Progressive Supranuclear Palsy (PSP): Virtual TrialNCT07863180 · 2026-09-01
RECRUITING
Individualized Transcranial Magnetic Stimulation in Parkinsonian DisordersNCT07570212 · 2025-12-22
RECRUITING
Prospective Multicenter Registry Study of Multiple System Atrophy in ChinaNCT07644013 · 2025-06-01
RECRUITING
Shanghai Clinical Cohort - Parkinson's Disease (Reserve)NCT07353463 · 2025-04-01
RECRUITING
Autologous suraL nervE Grafting to the Substantia nigrA in Patients With SynuclienopathiesNCT06683365 · 2025-02-25
RECRUITING
Neurodegenerative Diseases Progression Markers (MARKERS-NDD)NCT06596746 · 2024-09-09
RECRUITING
PET Imaging Evaluation of [11C]SY08NCT06098612 · 2024-05-01
RECRUITING
The Use of the CUE1/CUE1+ in People With Parkinson's Disease and Related DisordersNCT06174948 · 2024-03-25
RECRUITING
Study on Artificial Intelligence-Based Facial and Speech-Related Patterns in Parkinson's Disease and Their Digital BiomarkersNCT07392411 · 2023-07-25
RECRUITING
NYSCF Scientific Discovery BiobankNCT06203106 · 2022-11-10
RECRUITING
CPAP for the Treatment of Supine HypertensionNCT05489575 · 2022-06-23
RECRUITING
Insulin Resistance in Multiple System AtrophyNCT04250493 · 2020-10-28
RECRUITING
[18F]F-DOPA Imaging in Patients With Autonomic FailureNCT04246437 · 2020-02-04
RECRUITING
Neurodegenerative Diseases RegistryNCT04472130 · 2019-10-09
RECRUITING
Pain and Autonomic Symptoms in Parkinson's Disease and Atypical ParkinsonismsNCT05748028 · 2019-06-15
RECRUITING
Facilitating Diagnostics and Prognostics of Parkinsonian Syndromes Using NeuroimagingNCT03872102 · 2019-03-28
RECRUITING
Systematic Assessment of Laryngopharyngeal Function in Patients With Neurodegenerative DiseasesNCT04706234 · 2017-09-01
RECRUITING
The Swedish BioFINDER 2 StudyNCT03174938 · 2017-05-15
RECRUITING
Overnight Trials With Heat Stress in Autonomic Failure Patients With Supine HypertensionNCT03042988 · 2017-01-30
RECRUITING
Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic FailureNCT02897063 · 2016-09-01
RECRUITING
Modifiable Variables in Parkinsonism (MVP)NCT02194816 · 2012-09-01
RECRUITING
Natural History Study of SynucleinopathiesNCT01799915 · 2011-06-01
RECRUITING
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at SanfordNCT01793168 · 2010-07-01
RECRUITING
Cerebro Spinal Fluid Collection (CSF)NCT04844060 · 2010-02-01
RECRUITING
VisMemoPD Protocol: an Observational Pilot Study on Spatial and Topographical Memory in Patients With Parkinson's Disease and ParkinsonismNCT07827963 · 2026-09-01
NOT_YET_RECRUITING
Early Molecular Biomarkers for Differentiating Parkinsonian SyndromesNCT07604883 · 2026-06-04
NOT_YET_RECRUITING
hUC-MSC-sEV-001 Nasal Drops for Neurodegenerative DiseasesNCT06607900 · 2025-07-01
NOT_YET_RECRUITING
[18F] - FD17 PET Imaging of α-synuclein: A Clinical Study in α-synucleinopathy PatientsNCT06738862 · 2024-12-14
COMPLETED
Safety, Tolerability, and Pharmacokinetics of Exidavnemab in Patients With Parkinson's Disease and Patients With Multiple System AtrophyNCT06671938 · 2024-10-24
COMPLETED
Parkinson Atypical Rating of Oculometric Patterns Evaluated RoutinelyNCT06597071 · 2024-09-10
UNKNOWN
Prodromal Model of Parkinson's Disease Confined to The Peripheral Nervous SystemNCT06745011 · 2024-05-13
ENROLLING_BY_INVITATION
UB-312 in Patients With SynucleinopathiesNCT05634876 · 2023-05-31
COMPLETED
Differential Diagnosis Between Parkinson's Disease and Multiple System Atrophy Using Digital Speech Analysis - Part 2NCT05807373 · 2023-03-21
COMPLETED
Speech Accessibility ProjectNCT05889260 · 2023-03-15
COMPLETED
NMR Based Metabolomic Study of Serum Biomarkers in Patients With Parkinson's Disease and Atypical Parkinsonian SyndromeNCT06490926 · 2023-02-01
UNKNOWN
Unstructured Eye Tracking as a Diagnostic and Prognostic Biomarker in Parkinsonian DisordersNCT05638477 · 2022-12-01
UNKNOWN
Pre-Gene Therapy Study in Parkinson's Disease and Multiple System AtrophyNCT05699460 · 2022-09-29
COMPLETED
North American Prodromal Synucleinopathy Consortium Stage 2NCT05826457 · 2022-08-12
ENROLLING_BY_INVITATION
Optimizing BCI-FIT: Brain Computer Interface - Functional Implementation ToolkitNCT04468919 · 2022-07-15
COMPLETED
Community Outreach for Palliative Engagement -- Parkinson DiseaseNCT05222386 · 2022-04-26
ACTIVE_NOT_RECRUITING

Disease identity and terminology: MONDO. Trial relationships: ClinicalTrials.gov.